Here’s What Happened To Karyopharm Therapeutics Inc (KPTI) And PTC Therapeutics, Inc. (PTCT)

Karyopharm Therapeutics Inc (NASDAQ:KPTI) is down premarket heading into the close of this week, having initially taken a jump on a knee jerk market response to the release on Thursday. We think the company should stay pretty flat over the coming weeks, and then start to run into some mid year data releases rooted in its wider pipeline.

Bottom line, not great data, but far from the end of the line.

That’s more than can be said for the second company on this list – PTC.

PTC Therapeutics, Inc. (NASDAQ:PTCT) just announced results from a phase III investigation of a drug called Ataluren. The company was investigating the asset as part of this pivotal study in a cystic fibroses target indication, and this was a confirmatory trial in a subset of CF called nonsense mutation cystic fibrosis, which is widely regarded as one of the most difficult forms to treat in the disease type. The drug was generally well tolerated and the data derived from more than 1000 patients across multiple indications has shown it to be safe. However, as per the latest release, the trial failed to meet both its primary and secondary endpoints.

Unlike Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s asset, in the CF indication at least, this is the end of the line for Ataluren. The company is discontinuing investigation in this asset, and will add the data to that ever expanding pool if failed numbers to guide future endeavors in the space.

Unsurprisingly, this one is down considerably on the news. At last count, PTC Therapeutics, Inc. (NASDAQ:PTCT) was down 20% on its pre-release market capitalization.

Note: This article is written by Mark Collins and originally published at Market Exclusive.